Komori
Immuno-Biological Laboratories (4570) · InitiativeFirst stated

Approval, Insurance Coverage and Stable Supply of In Vitro Diagnostic Products for VEGF Measurement

First written in FY2021. . Latest entry: FY2021.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Approval, health insurance coverage, and stable supply of a VEGF-measuring in vitro diagnosticA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021First statedAnnual report

    「Together with a pharmaceutical company, we developed an in vitro diagnostic reagent for measuring serum VEGF levels, and development has been completed. Fujimoto Pharmaceutical Co., Ltd. has obtained marketing authorisation and completed its application for reimbursement coverage. We will be responsible for the stable manufacture and supply of this product.」

    For the VEGF assay used to assist in the diagnosis, treatment and monitoring of POEMS syndrome, development was completed, marketing authorisation was obtained, the application for reimbursement coverage was completed, and stable supply by us was noted.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Approval, Insurance Coverage and Stable Supply of In Vitro Diagnostic Products for VEGF Measurement | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori